Recent Financings Of Private Companies (03/2012)
This article was originally published in Start Up
Executive Summary
START-UP's monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies within the in vitro diagnostics, pharmaceuticals, research/analytical equipment & supplies, and medical device sectors.
You may also be interested in...
Deals In Depth: January 2021
BeiGene and Novartis penned a potential $2.2bn collaboration for the development, manufacture, and commercialization of BeiGene’s humanized IgG4 anti-PD-1 monoclonal antibody tislelizumab in the US, Canada, Mexico, member countries of the EU, the UK, Norway, Switzerland, Iceland, Liechtenstein, Russia, and Japan. Steris entered into a definitive agreement to acquire Cantel Medical, a global provider of infection prevention products and services primarily to endoscopy and dental customers. The total enterprise value of the deal is estimated at $4.6bn. Financing reached $10.5bn in biopharma, $984m in device, and $2.7bn in diagnostics.
Financing: 2020 Ends On A High Note For Medtech
During Q4, device company fundraising totaled $4.2bn; while in vitro diagnostic firms and research tools players raised $6.1bn.
Dealmaking Quarterly Statistics, Q4 2020
During Q4, biopharma merger and acquisition value reached $73.9bn and drew in $54.5bn in potential deal value from alliances. Device company M&A values reached $5.7bn, while in vitro diagnostic firms and research tools players completed M&A activity that totaled $3.3bn.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: